Misplaced Pages

ATC code C

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from ATCvet code QC) Pharmaceutical drug classification
ATC code C: Cardiovascular system
Other ATC codes

ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

References

  1. "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
  2. World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. "ATC/DDD Index 2022: code C". WHO Collaborating Centre for Drug Statistics Methodology.
  5. "ATCvet Index 2022: code QC". WHO Collaborating Centre for Drug Statistics Methodology.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
gastrointestinal tract
/ metabolism (A)
blood and blood
forming organs (B)
cardiovascular
system (C)
skin (D)
genitourinary
system (G)
endocrine
system (H)
infections and
infestations (J, P, QI)
malignant disease
(L01–L02)
immune disease
(L03–L04)
muscles, bones,
and joints (M)
brain and
nervous system (N)
respiratory
system (R)
sensory organs (S)
other ATC (V)
Cardiac glycosides (C01A)
Bufadienolides
Bufo
Scilla
Kalanchoe
Cardenolides
Digitalis
Strophanthus
Thevetia
Antiarrhythmic agents (C01B)
Channel blockers
class I
(Na channel blockers)
class Ia (Phase 0→ and Phase 3→)
class Ib (Phase 3←)
class Ic (Phase 0→)
class III
(Phase 3→, K channel blockers)
class IV
(Phase 4→, Ca channel blockers)
Receptor agonists
and antagonists
class II
(Phase 4→, β blockers)
A1 agonist
M2
α receptors
Ion transporters
Na/ K-ATPase
Cardiac stimulants excluding cardiac glycosides (C01C)
Adrenergic and
dopaminergic agents
Adrenergic agonists
α
β
mixed
Dopamine agonists
Both
Unknown/ungrouped
Phosphodiesterase inhibitors (PDE3I)
Other cardiac stimulants
Vasodilators used in cardiac diseases (C01D)
Nitrovasodilators
Quinolone vasodilators
Others
Sympatholytic (and closely related) antihypertensives (C02)
Sympatholytics
(antagonize α-adrenergic
vasoconstriction)
Central
α2-Adrenergic receptor agonists
Adrenergic release inhibitors
Imidazoline receptor agonists
Ganglion-blocking/nicotinic antagonists
Peripheral
Indirect
Monoamine oxidase inhibitors
VMAT inhibitors
Tyrosine hydroxylase inhibitors
Direct
α1-Adrenergic receptor blockers
Non-selective α-adrenergic receptor blockers
Other antagonists
Serotonin receptor antagonists
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension)
Nonsympatholytic vasodilatory antihypertensives (C02)
Nitrovasodilator (arterioles and venules)
Hydrazinophthalazines (arterioles)
Potassium channel openers (arterioles)
Calcium channel blockers (arterioles)
Diuretics (C03)
Sulfonamides
(and etacrynic acid)
CA inhibitors (at PT)
Loop (Na-K-Cl at AL)
Thiazides (Na-Cl at DCT,
Calcium-sparing)
Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)
ESC blockers
Aldosterone antagonists
Osmotic diuretics (PT, DL)
Vasopressin receptor inhibitors
(DCT and CD)
Other
Combination products
Peripheral vasodilators (C04)
Phenylethanolamine derivatives
Alpha blockers
Nicotinic acid and derivatives
Purine derivatives
Ergot alkaloids
Other peripheral vasodilators
Vasoprotectives (C05)
Antihemorrhoidals for topical use
corticosteroids
local anesthetics
other
Antivaricose therapy
heparins or heparinoids for topical use
sclerosing agents for local injection
other
Capillary stabilising agents
bioflavonoids
other
Beta blockers (C07)
β, non-selective
β1-selective
β2-selective
α1- + β-selective
Ion channel modulators
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors
("-pril")
AIIRAs
("-sartan")
Renin inhibitors
("-kiren")
Dual ACE/NEP inhibitors
Neprilysin inhibitors
Other
Lipid-lowering agents (C10)
GI tract
Cholesterol absorption inhibitors, NPC1L1
Bile acid sequestrants/resins (LDL)
Liver
Statins (HMG-CoA reductase, LDL)
Niacin and derivatives (HDL and LDL)
MTTP inhibitors (VLDL)
ATP citrate lyase inhibitors (LDL)
Thyromimetics (VLDL)
Blood vessels
PPAR agonists (LDL)
Fibrates
Others
CETP inhibitors (HDL)
PCSK9 inhibitors (LDL)
ANGPTL3 inhibitors (LDL/HDL)
Combinations
Other
Category:
ATC code C Add topic